![]() |
市場調查報告書
商品編碼
2085130
膀胱掃描儀市場:2026-2032年全球市場預測(依產品類型、成像技術、自動化程度、應用、最終用戶和通路分類)Bladder Scanners Market by Product Type, Imaging Technology, Automation, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,膀胱掃描儀市場將成長至 2.5185 億美元,複合年成長率為 6.33%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 1.6383億美元 |
| 預計年份:2026年 | 1.7393億美元 |
| 預測年份 2032 | 2.5185億美元 |
| 複合年成長率 (%) | 6.33% |
膀胱掃描儀是一種非侵入性超音波設備,用於評估膀胱容量和排尿後殘餘尿量,幫助臨床醫生評估閉尿症,同時減少不必要的導尿。它們在急診、長期照護、復健、泌尿系統、急診醫學、產科、術後恢復和居家醫療中的作用日益重要。
這項需求得到了明確的臨床優先事項的支持。根據美國疾病管制與預防中心 (CDC) 統計,約 75% 的醫院獲得尿道感染與導尿管相關,15% 至 25% 的住院患者在住院期間會插入導尿管。鑑於這些事實,膀胱掃描儀在導尿管管理、感染預防、提高營運效率和以患者為中心的泌尿科護理中發揮核心作用。
膀胱掃描儀領域正從獨立式超音波設備轉變為連網、工作流程整合的床邊診斷工具。醫院在評估設備時,不僅關注硬體規格,也越來越重視準確性、易用性、清潔流程、便攜性、電池續航時間、互通性、自動記錄功能以及訓練要求等因素。
人工智慧 (AI) 正透過自動影像解讀、膀胱邊界檢測、掃描引導、品管和決策支援提示等功能,逐步提升膀胱掃描儀的效能。這些功能可以減少操作人員的差異,尤其是在護理師和技術人員需要在時間限制下進行掃描的高流量科室。
亞太地區的需求成長主要受日本、中國、韓國、澳洲和印度等國龐大的病患數量、醫院擴建、手術量增加以及人口老化等因素所驅動。北美地區仍然是應用新技術的領先地區,因為感染預防項目、泌尿系統規範、與電子健康記錄的整合以及以價值為導向的醫療模式正在推動相關技術的發展,這些技術能夠減少不必要的導尿管使用,並支持可衡量的患者安全結果。
東協地區的需求與新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國醫院容量的擴大、醫療旅遊的發展以及公共部門的現代化密切相關。作為國家醫療衛生轉型計畫的一部分,海灣合作理事會(GCC)成員國優先發展高品質的醫院技術,從而推動了對聯網床邊護理設備的需求,這些設備能夠提高急診、外科和泌尿系統的效率。
美國透過導尿管相關尿道感染(CAUTI)預防計畫、大規模醫院網路以及積極推廣床邊超音波工作流程,發揮主導作用。另一方面,加拿大則強調標準化護理、感染控制以及各省醫療保健系統內醫療服務的公平取得。墨西哥和巴西則從私立醫院的擴張、公共採購流程的完善以及床邊診斷工具的廣泛應用中看到了商機。
產業領導者應優先考慮臨床有效性、易用性和工作流程整合。採購團隊越來越希望獲得能夠證明以下幾點的檢驗:減少不必要的導尿、更快地評估膀胱容量、可靠地測量排尿後殘餘尿量、降低操作者差異性,以及與感染預防政策的兼容性。
本執行摘要基於二手研究,使用了經核實的公共領域和機構材料,包括來自美國疾病控制與預防中心、世界衛生組織、美國食品藥品監督管理局、歐盟委員會、經合組織和國家衛生組織的指導和數據,以及關於閉尿症、導尿管相關尿道感染、排尿功能護理和床邊超聲的檢驗評審臨床超音波。
膀胱掃描儀正從泌尿系統的小眾工具發展成為感染控制、閉尿症管理、排尿功能護理和病人安全方面必不可少的床邊檢測技術。人口老化、導尿管的合理使用、電子病歷的普及以及醫院工作流程的現代化,共同為膀胱掃描儀的研發帶來了巨大的發展機會。
The Bladder Scanners Market is projected to grow by USD 251.85 million at a CAGR of 6.33% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 163.83 million |
| Estimated Year [2026] | USD 173.93 million |
| Forecast Year [2032] | USD 251.85 million |
| CAGR (%) | 6.33% |
Bladder scanners are noninvasive ultrasound devices used to estimate bladder volume and post-void residual urine, helping clinicians evaluate urinary retention while reducing unnecessary catheterization. Their role is increasingly important across acute care, long-term care, rehabilitation, urology, emergency medicine, obstetrics, postoperative recovery, and home health settings.
Demand is supported by well-documented clinical priorities. The CDC states that approximately 75% of hospital-acquired urinary tract infections are associated with urinary catheters, and 15% to 25% of hospitalized patients receive urinary catheters during their stay. These facts make bladder scanners central to catheter stewardship, infection prevention, workflow efficiency, and patient-centered continence care.
The bladder scanners landscape is shifting from stand-alone ultrasound equipment toward connected, workflow-integrated point-of-care diagnostic tools. Hospitals increasingly evaluate devices based on accuracy, ease of use, cleaning protocols, portability, battery life, interoperability, automated documentation, and training requirements rather than hardware specifications alone.
Aging demographics are reinforcing demand. The World Health Organization reports that by 2030, one in six people globally will be aged 60 years or older, increasing the clinical burden of urinary retention, benign prostatic hyperplasia, neurogenic bladder, postoperative retention, and incontinence management. This is accelerating adoption in both hospital and non-hospital care settings.
Artificial intelligence is beginning to improve bladder scanner performance through automated image interpretation, bladder boundary detection, acquisition guidance, quality control, and decision-support prompts. These capabilities can reduce operator variability, particularly in high-throughput departments where nurses and technicians perform scans under time pressure.
AI-enabled bladder scanners also support documentation and longitudinal monitoring by linking scan results to electronic health records. However, adoption depends on validated algorithms, cybersecurity safeguards, transparent clinical evidence, human oversight, and compliance with medical device regulations such as FDA quality system expectations, EU Medical Device Regulation requirements, and emerging good machine learning practices.
Asia-Pacific is supported by large patient populations, hospital expansion, rising surgical volumes, and aging trends in Japan, China, South Korea, Australia, and India. North America remains a leading adoption region because infection prevention programs, urology protocols, electronic health record integration, and value-based care models encourage technologies that reduce avoidable catheter use and support measurable patient safety outcomes.
Latin America is gaining traction through private hospital modernization in Brazil and Mexico, while Europe is shaped by standardized procurement, MDR compliance, antimicrobial resistance initiatives, and strong continence care pathways. The Middle East is investing in advanced hospital infrastructure across GCC countries, and Africa shows long-term opportunity where portable, easy-to-clean bladder scanners can support referral hospitals, maternal care, rehabilitation, and mobile care programs.
ASEAN demand is linked to expanding hospital capacity, medical tourism, and public-sector modernization in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are prioritizing premium hospital technologies as part of national healthcare transformation agendas, supporting demand for connected point-of-care devices that improve efficiency across emergency, surgical, and urology departments.
The European Union emphasizes device safety, clinical evidence, data protection, and procurement transparency under MDR and national health technology assessment practices. BRICS countries combine large patient pools with growing local manufacturing ambitions and hospital infrastructure investment. G7 markets lead in clinical protocols, infection prevention benchmarks, and reimbursement-linked quality metrics, while NATO healthcare systems value portable diagnostic tools for military medicine, rehabilitation, field care, and veteran health services.
The United States leads through CAUTI prevention programs, large hospital networks, and strong adoption of point-of-care ultrasound workflows, while Canada emphasizes standardized care, infection control, and equitable access across provincial health systems. Mexico and Brazil show opportunity in private hospital expansion, public procurement upgrades, and broader adoption of bedside diagnostic tools.
The United Kingdom, Germany, France, Italy, and Spain benefit from mature urology and continence care pathways, hospital quality programs, and emphasis on reducing catheter-associated complications, while Russia maintains demand across large regional hospital systems. China and India offer scale through hospital investment, rising urologic disease management needs, and expanding surgical care capacity. Japan, Australia, and South Korea support premium adoption through aging populations, advanced clinical practice, digital health readiness, and technology-forward healthcare systems.
Industry leaders should prioritize clinical validation, usability, and workflow integration. Procurement teams increasingly expect evidence showing reduced unnecessary catheterization, faster bladder volume assessment, reliable post-void residual measurement, lower operator variability, and compatibility with infection prevention policies.
Manufacturers should invest in AI-assisted acquisition, EHR connectivity, cybersecurity, durable portable designs, simplified cleaning, and training tools for bedside and outpatient use. Commercial teams should align messaging with CAUTI reduction, nursing efficiency, postoperative retention protocols, urology care pathways, rehabilitation, and long-term care needs. Regional strategies should reflect regulatory requirements, distributor capabilities, training infrastructure, language localization, and service availability.
This executive summary is built from secondary research using verified public-domain and institutional sources, including guidance and data from the CDC, WHO, FDA, European Commission, OECD, national health agencies, and peer-reviewed clinical literature on urinary retention, catheter-associated urinary tract infection, continence care, and point-of-care ultrasound.
The methodology emphasizes triangulation across clinical guidelines, demographic indicators, regulatory frameworks, hospital procurement trends, infection prevention priorities, and regional healthcare infrastructure developments. Market interpretation avoids unsupported revenue claims and instead focuses on evidence-backed demand drivers, adoption barriers, clinical use cases, and technology trends shaping bladder scanner deployment.
Bladder scanners are moving from niche urology tools to essential point-of-care technologies for infection prevention, urinary retention management, continence care, and patient safety. The strongest opportunities are emerging where aging populations, catheter stewardship, digital documentation, and hospital workflow modernization converge.
Future competitiveness will depend on accuracy, usability, AI-enabled support, regulatory readiness, cybersecurity, and evidence that devices improve clinical and operational outcomes. Organizations that combine validated technology with strong training, service support, and region-specific commercialization strategies will be best positioned in the evolving bladder scanners landscape.